Sarasin & Partners LLP Invests $242.99 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sarasin & Partners LLP acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 488,325 shares of the medical research company's stock, valued at approximately $242,991,000. Thermo Fisher Scientific accounts for approximately 2.4% of Sarasin & Partners LLP's investment portfolio, making the stock its 19th biggest position. Sarasin & Partners LLP owned 0.13% of Thermo Fisher Scientific as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of TMO. LaFleur & Godfrey LLC grew its stake in shares of Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock worth $15,486,000 after acquiring an additional 2,488 shares during the period. Brighton Jones LLC grew its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the period. Union Bancaire Privee UBP SA bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $71,877,000. Revolve Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the period. Finally, Heck Capital Advisors LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $567,000. Institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Trading Down 0.8%

Shares of TMO stock traded down $3.22 during trading hours on Thursday, reaching $400.44. The company's stock had a trading volume of 1,287,637 shares, compared to its average volume of 1,893,694. The stock has a market capitalization of $151.16 billion, a P/E ratio of 24.23, a P/E/G ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a one year low of $390.50 and a one year high of $627.88. The firm's fifty day simple moving average is $424.35 and its 200 day simple moving average is $497.38. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business's quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company earned $5.11 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TMO shares. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Scotiabank dropped their price objective on Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a report on Friday, April 25th. UBS Group dropped their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Finally, Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and an average price target of $605.30.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.